Studies evaluating ASCT in transformed lymphoma
| Reference . | N . | OS, % . | PFS or EFS, % . | Median follow-up, y . | Rituximab era . |
|---|---|---|---|---|---|
| 50 | 50 | 2 y, 64 | 5-y PFS. 30 Median PFS, 1.1 y | 4.9 | No |
| 5 y, 51 | |||||
| 51 | 35 | 5 y, 37 | 5-y PFS, 36 | 4.3 | No |
| 72 | 33 | 2 y, 72 | 2-y EFS, 47 | 1.7 | No |
| 5 y, 72 | 5-y EFS, 33 | ||||
| 52 | 27 | 5 y, 58 | 5-y DFS, 46 | 3.0 | No |
| 55 | 27 | Median, 8.5 y | N/A | 2.4 | No |
| 53 | 23 | 5 y, 56 | 5-y PFS, 25 | 15 | No |
| 56 | 22 | Median, 4.6 y | Median EFS, 1.4 y | 5.5 | No |
| 57 | 32 | 5 y, 32 | 5-y PFS, 47 | 6.25 | No |
| 47 | 24 | 3 y, 52 | 3-y PFS, 40 | 3.16 | No |
| 64 | 51 | 5 y, 62 | 5 y, 45 | 3 | Yes |
| 45 | 50 | 2 y, 83 | N/A | 3.4 | Yes |
| 62 | 18 | 2 y, 82 | 2-y PFS, 59 | 3.3 | Yes |
| 58 | 97 | 5 y, 65 | 5-y PFS, 55 | 7.5 | Yes |
| 60 | 50 | 3 y, 54 | 3-y PFS, 42 | 3.3 | Yes |
| 65 | 25 | 3 y, 64 | 3-y RFS, 59 | 2.1 | Yes |
| 66 | 65 | 5 y, 65 | 5-y PFS, 57 | NA | Yes |
| Reference . | N . | OS, % . | PFS or EFS, % . | Median follow-up, y . | Rituximab era . |
|---|---|---|---|---|---|
| 50 | 50 | 2 y, 64 | 5-y PFS. 30 Median PFS, 1.1 y | 4.9 | No |
| 5 y, 51 | |||||
| 51 | 35 | 5 y, 37 | 5-y PFS, 36 | 4.3 | No |
| 72 | 33 | 2 y, 72 | 2-y EFS, 47 | 1.7 | No |
| 5 y, 72 | 5-y EFS, 33 | ||||
| 52 | 27 | 5 y, 58 | 5-y DFS, 46 | 3.0 | No |
| 55 | 27 | Median, 8.5 y | N/A | 2.4 | No |
| 53 | 23 | 5 y, 56 | 5-y PFS, 25 | 15 | No |
| 56 | 22 | Median, 4.6 y | Median EFS, 1.4 y | 5.5 | No |
| 57 | 32 | 5 y, 32 | 5-y PFS, 47 | 6.25 | No |
| 47 | 24 | 3 y, 52 | 3-y PFS, 40 | 3.16 | No |
| 64 | 51 | 5 y, 62 | 5 y, 45 | 3 | Yes |
| 45 | 50 | 2 y, 83 | N/A | 3.4 | Yes |
| 62 | 18 | 2 y, 82 | 2-y PFS, 59 | 3.3 | Yes |
| 58 | 97 | 5 y, 65 | 5-y PFS, 55 | 7.5 | Yes |
| 60 | 50 | 3 y, 54 | 3-y PFS, 42 | 3.3 | Yes |
| 65 | 25 | 3 y, 64 | 3-y RFS, 59 | 2.1 | Yes |
| 66 | 65 | 5 y, 65 | 5-y PFS, 57 | NA | Yes |
EFS, event-free survival; PFS, progression-free survival.